Concourse Financial Group Securities, Inc. Vaxxinity, Inc. Transaction History

Concourse Financial Group Securities, Inc.

$1.56 Billion
Q2 2024

11 transactions

Quarter	Operation	Price Per share
Q1 2024 Apr 30, 2024	BUY	$0.62 - $0.86 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$0.7 - $1.31 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$1.25 - $3.0 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$1.25 - $3.0 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$1.73 - $2.79 $0 - $0
Q1 2023 May 15, 2023	BUY	$1.43 - $4.24 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$1.31 - $2.62 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$1.64 - $2.48 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$1.55 - $6.95 $0 - $0
Q1 2022 May 09, 2022	BUY	$3.7 - $8.6 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$5.55 - $18.46 $0 - $0

Others Institutions Holding VAXX

# of Institutions

Shares Held

469K

Call Options Held

Put Options Held

View Full List

About Vaxxinity, Inc.

Ticker VAXX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 112,150,000
Market Cap $1.12M
Description
Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology and coronaviruses in the United States. The company engages in developing UB-311 that targets toxic forms of aggregated amyloid-b in the brain to fight Alzheimer's disease (AD) that is in phase 2 clinical trial; UB-312 that...

More about VAXX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account